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Deubiquitinating proteases reverse protein ubiquiti-
nation and rescue their target proteins from destruc-
tion by the proteasome. USP2, a cysteine protease
and a member of the ubiquitin specific protease family,
is overexpressed in prostate cancer and stabilizes
fatty acid synthase, which has been associated with
the malignancy of some aggressive prostate cancers.
Here, we report the structure of the human USP2 cata-
lytic domain in complex with ubiquitin. Ubiquitin uses
two major sites for the interaction with the protease.
Both sites are required simultaneously, as shown by
USP2 inhibition assays with peptides and ubiquitin
mutants. In addition, a layer of ordered water mole-
cules mediates key interactions between ubiquitin
and USP2. As several of those molecules are found
at identical positions in the previously solved USP7/
ubiquitin-aldehyde complex structure, we suggest
a general mechanism of water-mediated ubiquitin rec-
ognition by USPs.
Introduction
Posttranslational modification with ubiquitin regulates
protein stability and localization and is crucial for
homeostasis of eukaryotic cells. In a multistep process
involving three classes of enzymes called E1 (ubiquitin
activating), E2 (ubiquitin conjugating), and E3 (ubiquitin
ligating), an isopeptide bond is formed between the
C-terminal group of ubiquitin and a lysine 3-amino group
of the targeted protein. Ubiquitination is reversed by
a number of proteases that specifically recognize ubiq-
uitinated proteins and remove the ubiquitin tag by
hydrolyzing the isopeptide bond. Currently almost 100
putative deubiquitinating proteases (DUBs; or ubiqui-
tin-specific processing proteases UBP) belonging to 5
distinct families are known (Amerik and Hochstrasser,
2004; Nijman et al., 2005), the majority of which are cys-
teine proteases, including 4 human ubiquitin C-terminal
hydrolyases (UCHs) and 54 human ubiquitin-specific
proteases (USPs). USPs are multidomain proteases
that vary in size and complexity but share a certain de-
gree of homology within their catalytic units, namely
within three regions termed the Cys-, His-, and QQD-
Box (Quesada et al., 2004). In most USPs, the catalytic
unit is preceded and followed by additional domains
*Correspondence: martin.renatus@novartis.comthat are believed to determine subcellular localization
and substrate recognition. Little is known about the
physiological function of most human USPs, and spe-
cific substrates often remain elusive. A well-studied
example is USP7 (HAUSP), which stabilizes both p53
and mdm2, thereby playing an important role in the
p53 pathway (Li et al., 2002, 2004; Cummins et al.,
2004; Cummins and Vogelstein, 2004). Several publica-
tions describe the structural basis for substrate recogni-
tion by USP7 (Hu et al., 2002, 2006; Sheng et al., 2006).
Less is known about the structure and function of
USP2. It is overexpressed in human prostate cancer
and prolongs the half-life of fatty acid synthase (Graner
et al., 2004), a metabolic enzyme associated with the
malignancy of aggressive prostate cancer (Baron
et al., 2004). In addition, USP2 itself has oncogenic prop-
erties in vivo and in vitro that are linked to its proteolytic
activity (Priolo et al., 2006). Mdm2 appears to be another
substrate for USP2, indicating that USP2 also plays
a role in the regulation of the p53 pathway (L.F. Steven-
son et al., submitted).Together, these data provide a first
rationale for USP2-directed therapies in the treatment of
prostate cancer. A possible strategy is the inhibition of
its proteolytic activity.
To aid the discovery of active site-directed inhibitors,
we solved the three-dimensional structure of USP2 in
complex with ubiquitin at a resolution of 1.85 A˚. We sug-
gest a general mode of substrate recognition by USPs,
where conserved water molecules mediate interactions
between the ubiquitin core (residues 1–71) and the pro-
tease. The five C-terminal residues of ubiquitin (Arg72-
Leu73-Arg74-Gly75-Gly76) bind into the active site cleft
without making covalent interactions with the active site
cysteine. Kinetic studies with peptidic substrates and
truncated ubiquitin mutants show that neither the
C-terminal peptide nor ubiquitin deletion mutants lack-
ing the C-terminal residues bind to USP2 with detect-
able affinity.
Results
Overall Structure of the USP2/Ubiquitin Complex
USP2 is reported to exist in several isoforms (http://
merops.sanger.ac.uk/), and it is unclear how these differ
in function. The isoforms consist of an N-terminal region
of variable length and a 347 amino acid large C-terminal
domain. The C-terminal domain possesses the se-
quence signatures of an USP catalytic domain (Figure 1).
In the largest isoform, USP2a, the catalytic domain is
preceded by 258 amino acids, in the shortest by only
6. We focused our studies on the conserved catalytic
domain. For clarity, the construct comprising residues
259–605 will hereon be referred to as USP2. USP2 was
produced with high yields as recombinant protein in
E. coli, and it cleaved the synthetic substrate ubiquitin-
AMC with a catalytic efficiency kcat/KM of 2.6 3 10
5
M21s21 (Table 1). To facilitate the comparison of key res-
idues, we refer the numbering of USP2 to that of USP7
(Figure 1), for which the first USP structure was pub-
lished (Hu et al., 2002).
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1294Despite repeated trials with numerous USP2 prepara-
tions, we failed to crystallize ligand-free USP2. This
might be due to the strong tendency of USP2 to aggre-
Figure 1. Structure-Based Sequence Alignment of the Human USP2
and USP7 Catalytic Domains
Ca positions that are in a structural alignment within 1.7 A˚ are high-
lighted by gray boxes. USP2 residues are numbered according to
the corresponding USP7 residues; insertion loops in USP2 relative
to USP7 are numbered alphabetically. Active-site residues (catalytic
triad: Cys223, His464, Asp/Asn481; and oxyanion hole: Asn218) and
the four cysteine residues (Cys334, Cys337, Cys381, Cys384) coor-
dinating a metal ion are shown in bold. USP2 residues poorly defined
by electron density are underlined. Secondary structure elements
are colored as in Figure 2B (thumb, gray; fingers, lime; palm, blue).
Forty-seven USP2 residues that are within 4 A˚ of ubiquitin are de-
noted by triangles. Open triangles, interactions with the ubiquitin
core (ubiquitin residues 1–71); solid black triangles, interactions
with the ubiquitin C terminus (ubiquitin 72–76); solid gray triangles,
interactions with both ubiquitin core and C terminus. A consensus
sequence, based on the alignment of 54 human USPs (Quesada
et al., 2004) and denoted as ‘‘all USP,’’ is included in the alignment
(bold capital letters, identical in more than 90% of the sequences;
capital letters, identical in more than 80% of the sequences; small
letters, identical in more than 60% of the sequences). Regions of
high sequence conservation within the human USPs are highlighted
with boxes: Cys-box (215–229), QDE-box (292–305), and His-box
(446–468, 477–486, and 512–520).gate, which is highly accelerated at temperatures below
10C. Interestingly, complexation of USP2 with ubiqui-
tin-aldehyde (resulting in a covalent complex) or unmod-
ified ubiquitin (resulting in a noncovalent complex) pre-
vented aggregation and yielded crystals that grew
overnight. Analysis by SDS-PAGE showed that the crys-
tals contain both protein components, USP2 and ubiqui-
tin (data not shown). Diffraction properties improved
significantly upon dehydration of the crystals (Abergel,
2004), and a data set with 1.85 A˚ resolution was
obtained. The structure could be solved by molecular
replacement with USP7 as search molecule.
The USP2 structure contains nine a helices and 14
b strands (Figure 2A). Its overall shape resembles a cup-
ped hand with the approximate dimensions of 35 A˚ 3
40 A˚ 3 65 A˚ and comprises three domains termed
thumb, palm, and fingers (Figure 2B), an analogy first
used for USP7 (Hu et al., 2002). The finger domain is
formed by a four-stranded b sheet (s1, s2, s4, s7), which
is flanked by helix h50. This helix is absent in USP7, while
two short strands at the tip of the fingers, present in
USP7 (s5 and s6), are missing in USP2 (Figure 2C). The
thumb is formed by seven helices (h1–h6, including
h50). Compared to USP7, it lacks two additional C-termi-
nal helices (h9 and h10). The palm connects fingers and
the thumb and is formed by several b strands and a heli-
ces (s3, s8–s14, h7, and h8). Residues 214–229 (Cys-
box) and 292–305 (QDE-box) of the thumb, as well as
residues 446–486, 477–486, and 512–520 of the palm
(His-box), form the active site (Quesada et al., 2004).
The conserved residues Cys223, His464, and Asn481
form the catalytic triad, and Asn218 the oxyanion hole
(http://merops.sanger.ac.uk/). The cupped hand of
USP2 nicely accommodates ubiquitin, an 8 kDa small
and spherical molecule with a diameter of approxi-
mately 25 A˚. In the complex, 3850 A˚2 of the solvent-
accessible surface is buried, which corresponds to
roughly 40% of the ubiquitin surface. USP2 and ubiquitin
have complementary shapes, providing a first structural
explanation for the high selectivity of USPs for ubiquitin
substrates.
Metal Binding Site
In USP2, a metal binding site is located between the two
loops connecting strands s1–s2 and s4–s7, where four
cysteine residues (Cys334, Cys337, Cys381, Cys384)
coordinate a metal ion (Figure 2A). The corresponding
Sg-metal ion distances are 2.46 A˚, 2.38 A˚, 2.40 A˚, and
2.47 A˚, close to the reported ideal distance (2.35 6
0.09 A˚) for structural zinc binding sites in proteinsTable 1. Steady-State Kinetic Parameters for the Hydrolysis of AMC Substrates by UCH-L3 and USP2
USP2
KM (M) kcat (s
21) kcat/KM (M
21 s21) [Enz] (M)
Ubiquitin-AMC 554 3 1029 0.14 252 3 103 1.5 3 1029
Ac-RLRGG-AMC inactive inactive inactive 1.0 3 1026
Ac-HLVLRLRGG-AMC inactive inactive inactive 1.0 3 1026
UCH-L3
KM (M) kcat (s
21) kcat/KM (M
21 s21) [Enz] (M)
Ubiquitin-AMC 32 3 1029 7.34 229 3 106 3.0 3 10212
Ac-RLRGG-AMC 3.0 3 1024 7.6 3 1026 2.5 3 1022 5.0 3 1027
Ac-HLVLRLRGG-AMC 7.3 3 1025 1.8 3 1025 2.5 3 1021 6.0 3 1027
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The catalytic domain consists of residues 259–605 of full-length USP2. Secondary structure elements are named according to the USP7 structure
(Hu et al., 2002). The loops connecting h5 and h50 as well as s3 and h7 are poorly defined by electron density (see also Figure 1) and are therefore
omitted from the final model. Dotted lines highlight these gaps.
(A) Overall structure of the USP2/ubiquitin complex (blue/orange ribbon). The active-site residues Asn218, Cys223, His464, and Asn481 as well as
the metal binding site Cys334, Cys337, Cys381, and Cys384 are shown as sticks, and the zinc ion is shown as a pink sphere.
(B) Overall structure of USP2. Secondary elements forming the palm, the fingers, and the thumb are painted in blue, lime, and gray, respectively.
Ubiquitin has been omitted for clarity.
(C) Superposition of the catalytic domain of USP2 in blue with the catalytic domain of USP7 in salmon (1BNF). The ubiquitin molecules of both
complex structures superimpose perfectly and have been omitted for clarity.
(D) Solvent molecules (blue) mediate the binding of ubiquitin (orange) to USP2 (gray surface).
(E) Solvent molecules mediating the binding of ubiquitin are shown as blue spheres, and the molecular surface corresponding to USP2 residues
within 4.0 A˚ of the ubiquitin molecule is highlighted in orange. The ubiquitin molecule has been omitted for clarity.
(F) Superimposition of buried water molecules (USP2/ubiquitin, blue; USP7/ubiquitin-aldehyde, salmon). Stars highlight equivalent water posi-
tions. USP2 is shown as a gray transparent surface. Lys407 of USP2, replacing a water molecule present in the USP7/ubiquitin-aldehyde struc-
ture, is shown as sticks.(Alberts et al., 1998). Based on these distance criteria
and on a MAD experiment (see Supplemental Data),
we conclude that this metal ion is a tightly bound zincion. This CXXC-Xn-CXXC metal binding motif is common
among USPs (Krishna and Grishin, 2005). Of 54 (Ques-
ada et al., 2004) putative human USPs, the motif is
Structure
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USP25, USP28, USP34, and USP39. Also the viral prote-
ase SARS-CoV PLpro, which has deubiquitinating activ-
ity and is structurally similar to human USPs (Ratia et al.,
2006), contains an intact zinc binding site at the ho-
mologous position. The two CXXC sequence patterns
are mostly separated by approximately 50 residues,
although in some cases (e.g., USP4 and USP6), an addi-
tional domain of up to 350 amino acids is inserted at this
position. Based on the structure of human USP7, it has
been predicted that the finger domain of USPs is a
zinc ribbon (Krishna and Grishin, 2005), a structure mod-
ule that is known to serve as an interaction domain
in many proteins. Krishna and Grishin hypothesized
that the zinc ribbon domain has been inserted into a
papain-like protease domain, the ancestor of USPs, to
serve as a scaffold for ubiquitin recognition. In some
USPs, including USP7, several of the four cysteine resi-
dues have been mutated during evolution, and the zinc
binding ability was lost while the fold was maintained.
This indicates that a metal binding site is not required
for deubiquitinating activity. Therefore, the precise func-
tion of the zinc binding site in USP2 and other USPs
remains elusive.
Specific Interactions of USP2 with Ubiquitin
The structure shows USP2 in a noncovalent complex
with ubiquitin. Ubiquitin uses two sites for the interac-
tion with USP2. Its core (residues 1–71; throughout the
paper ubiquitin residues are given in italics, USP2 resi-
dues in normal font) binds into the cupped hand con-
tacting residues of all three structural elements, fingers,
thumb, and palm, while its five C-terminal residues (72–
76) bind into a narrow channel and reach for the active
site cysteine (Figure 2D). As many as 30 USP2 residues
are within 4 A˚ of the ubiquitin core. Among those, 12 are
engaged in H bond and salt bridge interactions: 5 are
found at the tip of the fingers (Ser341, Asp345,
Asp371, Asp376, Glu377), involving ubiquitin residues
from strands s1 and s2 and from the loop preceding
strand s4. The others are located on the thumb
(Asp295, Glu298, Arg301, Glu316, Lys407, Thr418) and
palm (Leu366), interacting with the ubiquitin residues
following strands s1 and s4 and the ones preceding
s3. However, for a significant fraction of the total contact
area the interactions are indirect, as numerous solvent
molecules mediate H bond interactions between ubiqui-
tin backbone and USP2 side chain/backbone atoms
(Figures 2D and 2E). In total, 25 solvent molecules are
located in the region between the tip of the fingers and
the thumb, and most of them are lined up along strands
s1, s2, and s3 (Figure 2F).
The C terminus of ubiquitin Arg72-Leu73-Arg74-Gly-
75-Gly76 binds with its Gly-Gly motif into a narrow
channel reaching for the active site cysteine (Figure 2D).
The backbone atoms of Leu73, Arg74, and Gly75 form
a network of six H bonds with USP2 (Figure 3A). The
side chain of Arg74 is solvent accessible, while Leu73
binds into a hydrophobic pocket and the guanidinium
group of Arg72 interacts with Glu298. No nearby
countercharge neutralizes the negative charge of the
ubiquitin carboxyl terminus. Instead, three H bond inter-
actions with Cys223N, Asn221Nd2, and Gln293N32 sta-
bilize the C terminus in its conformation. The negativecharge of the Gly76 carboxy group does not seem to
be well balanced in the complex, especially as the
Cys223 Sg atom is most likely deprotonated (see Dis-
cussion), leading to electrostatic repulsion between
the two negatively charged moieties. Indeed, the side
chain of Cys223 seems to exist in two rotamers: a small
population adopts the catalytically active conformation,
which was observed in the USP7/ubiquitin-aldehyde
complex (Figure 3B), as suggested by a very weak dif-
ference electron density peak. Mostly, Cys223 is ro-
tated by 120 with Sg pointing away from ubiquitin
Gly76 and in the direction of Asp482 (Figure 3B). The
electron density of Asp482 is rather poor, although all
neighboring side chains are well defined, indicating in-
creased mobility.
Comparison of Ubiquitin Binding to USP2 and USP7
Despite a limited sequence identity ofw24%, the overall
fold of the USP2 and USP7 catalytic domains is con-
served. The two structures superimpose with an rmsd
of 1.25 A˚ for 262 Ca positions, which corresponds to
75% of the USP2 residues (Figures 1 and 2C). A similar
Figure 3. Substrate Binding Region of USP2 and USP7
(A) USP2/ubiquitin complex: the five C-terminal residues of ubiqui-
tin, Leu-Arg-Leu-Gly-Gly, are shown as orange sticks. USP2 side
chains that are within 4.0 A˚ of the ligand as well as residues
Asn218, His464, and Asn481 of the active site are shown as sticks.
Putative hydrogen bonds are indicated by yellow dotted lines.
(B) Superimposition of the binding region of USP2 (blue) and USP7
(salmon): residues forming the substrate recognition pocket for
the ubiquitin C terminus as well as the catalytic Cys223 are shown
as sticks. Only USP7 residues that differ from USP2 are labeled.
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where 256 Ca positions can be aligned with an rmsd of
1.43 A˚. However, as the USP14/ubiquitin-aldehyde com-
plex (Hu et al., 2005) has been solved at significantly
lower resolution than the corresponding complex with
USP7 (3.5 A˚ versus 2.3 A˚), we focus in our structural
comparison on USP7. Structural elements that directly
interact with ubiquitin, namely the base of the fingers
and the surroundings of the active site, superimpose es-
pecially well, ensuring conservation of ubiquitin binding.
Indeed, the 76 ubiquitin Ca positions of the USP2 and
USP7 complexes differ with an rmsd of only 0.74 A˚.
This high structural similarity shows that the different
protocols for the preparation of USP/ubiquitin com-
plexes have no influence on the overall ubiquitin binding
mode. Ubiquitin was used for the USP2/ubiquitin com-
plex, while ubiquitin-aldehyde was used for the forma-
tion of corresponding USP7 complex. Ubiquitin-alde-
hyde is a chemically modified form of ubiquitin and
highly potent USP inhibitor, where the terminal carboxy
group has been reduced to an aldehyde for increased
electrophilicity and affinity. In the resulting USP/ubiqui-
tin-aldehyde complex, a covalent bond between inhibi-
tor and protease is formed, representing a classical
transition state mimetic for cysteine protease substrate
complexes (Westerik and Wolfenden, 1972). Therefore,
the USP7/ubiquitin-aldehyde and the USP14/ubiquitin-
aldehyde complex structures reveal how USPs stabilize
the tetrahedral intermediate (‘‘oxyanion’’) that is formed
during catalysis. Instead, no covalent bond is formed in
the USP2/ubiquitin complex. The structure represents
the noncovalent protease/product complex, the last
step of peptide cleavage catalyzed by proteases. As
such, it can help explain the structural reasons for sub-
strate inhibition, a phenomenon that is observed in this
class of enzymes (see below).
Most USP residues that interact directly with ubiqui-
tin, both with the ubiquitin core (1–71) and the C termi-
nus (72–76), are conserved (Figure 1). The binding clefts
in USP2 and USP7 for the ubiquitin C terminus are al-
most identical. Only the loop around position 287 adopts
different conformations. Of the 20 USP residues that are
within 4 A˚ of the ubiquitin C-terminal penta-peptide, 14
are conserved, while residues at position 221, 224,
287, 294, 460, and 461 differ in sequence (Figure 3B).
All of these six amino acid exchanges except for the
one at position 221 (Asn in USP2, Ala in USP7) most
likely have no influence on the ubiquitin binding. The sig-
nificance of the exchange at position 221 is difficult to
rationalize, especially as this residue is highly conserved
in the USP family of proteases. In 42 USPs, including
USP2, USP5, and USP14, an asparagine is found at
this position, and in only six USPs, including USP7, an
alanine is found. In the USP2/ubiquitin complex,
Asn221 Nd is in close contact to one oxygen of the
Gly76 carboxylate, while Asn218 Nd (‘‘oxyanion hole’’)
interacts with the second C-terminal oxygen, an interac-
tion similar to the one observed in the USP7/ubiquitin-
aldehyde complex. Therefore, Asn221 together with
Asn218 contributes to the stabilization of the negative
charge on the ubiquitin C terminus (Figure 3A). In the
USP14/ubiquitin-aldehyde complex, where the ubiqui-
tin C terminus is covalently bound to the site cysteine
and only one C-terminal oxygen is present, Asn108(Asn218 in USP2) interacts with the hydroxyl of the thio-
hemiacetal, while Asn111 (Asn221 in USP2) makes no
specific interactions and is rotated away from the active
site. This comparison indicates that Asn221 plays a role,
not in the stabilization of the transition state during ca-
talysis, but rather in the stabilization of the enzyme prod-
uct. This way, Asn221 might contribute to product inhi-
bition (see below), and the high conservation of this
residue suggests this characteristic is shared by most
USPs. Unfortunately, so far, the catalytic properties of
only one other member of the USP family, USP5 or iso-
peptidase T, has been characterized extensively (Stein
et al., 1995). Also, USP5 has an asparagine at the corre-
sponding position and is inhibited by ubiquitin. The
question whether USPs, such as USP7, that don’t have
an asparagine at this position bind ubiquitin with lower
affinity and show less substrate inhibition remains
open until a detailed enzymatic characterization of these
enzymes becomes available.
USP residues interacting with the ubiquitin core are in
general poorly conserved (Figure 1), with the exception
of 12 USP2 residues (see above) that are engaged in di-
rect polar interactions. Among these 12 residues, 7 are
conserved. Of the 5 nonconserved residues, 2 interact
via their main-chain atoms (Leu366, Glu377), and only
3 (Glu316, Lys407, Thr418) are involved in interactions
that are not possible in USP7. Overall, the same mode
of ubiquitin recognition has been observed for USP14
(Hu et al., 2005). Based on the structural data and se-
quence conservation, it can be predicted that functional
USPs share not only the overall structure but also use
the described determinants for ubiquitin recognition
and binding.
Inhibition of USP2 by Ubiquitin and Ubiquitin
Truncation Mutants
After having shown that ubiquitin interacts with USP2
by using two sites, we tried to determine the individual
contribution of the isolated interactions to the ubiq-
uitin binding affinity. To this end, we first generated
ubiquitin and three C-terminally truncated mutants
(ubiquitin 1–74, ubiquitin 1–73, and ubiquitin 1–72) in
E. coli as reagents for enzymatic inhibition assays. The
heterologously expressed proteins were characterized
by 1H-NMR spectroscopy and differential scanning cal-
orimetry, by using endogenous ubiquitin purified from
bovine thymus as a reference. The reference sample
as well as all recombinant-expressed protein samples
unfolded in a cooperative manner with the transition
temperatures, Tm, in a similar range. The measured
Tm’s were 98.3C (reference sample, endogenous ubiq-
uitin), 91.9C (ubiquitin), 91.9C (ubiquitin 1–74), 90.7C
(ubiquitin 1–73), and 98.2C (ubiquitin 1–72), indicating
that the C-terminal truncations have no major influence
on protein stability. The 1H NMR spectra of the endoge-
nous and recombinant ubiquitin are largely identical.
In addition, truncated mutants show only minor differ-
ences compared to the reference (data not shown).
Taken together, these results indicate that heterologous
expression of ubiquitin in E. coli yields a properly folded
protein and that C-terminal truncations do not disturb
the structure of the ubiquitin core. As an additional con-
trol experiment, we measured a Ki of 0.27 mM for the
Structure
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ubiquitin-AMC. This Ki is close to the published value
of 0.3 mM (Wilkinson et al., 1999), which further validates
the experimental setup. Next, by using the same assay
format, the influence of ubiquitin on the proteolytic ac-
tivity of USP2 was analyzed. USP2 is inhibited by ubiqui-
tin with a Ki of 2.8 mM, which is in the same range as the
Ki of 3 mM for the related enzyme USP5, also known as
isopeptidase T (Dang et al., 1998). This shows that
USP2 binds ubiquitin with significant affinity, and it sug-
gests that product inhibition by ubiquitin is a general
feature of the USP family of proteases. The biological
significance of product inhibition is unknown. It might
play a role in the regulation of USP activity, as with
increasing intracellular ubiquitin concentration the deu-
biquitinating activity might be reduced. Yet, such an
inhibition will only be observed if the concentration of
free ubiquitin is in the same range as the Kd for the inter-
action between ubiquitin and the protease.
The structure of the USP2/ubiquitin complex shows
that ubiquitin uses two interaction sites: its core (resi-
dues 1–71) binds into the cupped hand interacting with
fingers and palm, and its C terminus (residues 72–76)
binds into the substrate cleft at the catalytic center. To
determine the contribution of each binding site to the to-
tal affinity, we analyzed the two binding events inde-
pendently. The contribution of the C-terminal peptide
was assessed by measuring the Michealis-Menten
parameters for two peptidic AMC substrates, consisting
of the last five and nine ubiquitin C-terminal residues,
respectively. Neither of the substrates is cleaved by
USP2 under the assay conditions (Table 1). This obser-
vation does not result from an unfavorable substrate
conformation, as UCH-L3 is able to cleave both Ac-
RLRGG-AMC and Ac-HLVLRLRGG-AMC, although with
significantly lower catalytic efficiency compared to
ubiquitin-AMC, but rather indicates that substrates do
not bind to USP2. This interpretation is further sup-
ported by an additional inhibition experiment showing
that the C-terminal peptide Ac-HLVLRLRGG has no ef-
fect on the proteolytic activity of USP2 (Table 2). Next,
the contribution of the ubiquitin core to the total binding
affinity was analyzed. The truncation mutants ubiquitin
1–72 and 1–73 affect the proteolytic activity of USP2
only marginally even at the highest inhibitor concentra-
tion used (Figure 4), indicating that the Ki for these mu-
tants is significantly higher then 100 mM. In summary,
Table 2. Inhibition of USP2
Inhibitor Ki (M)
Ubiquitina 2.8 6 0.14 3 1026
Ubiquitin 1–74b 1.0 6 0.09 3 1026
Ubiquitin 1–73c >1 3 1024
Ubiquitin 1–72d >1 3 1024
Ubiquitin 1–71e >1 3 1024
Ac-HLVLRLRGG-OHf >1 3 1024
a Full-length ubiquitin.
b Truncation mutants lacking Gly75-Gly76.
c Truncation mutants lacking Arg74-Gly75-Gly76.
d Truncation mutants lacking Leu73-Arg74-Gly75-Gly76.
e Truncation mutants lacking Arg72-Leu73-Arg74-Gly75-Gly76.
f Ubiquitin C-terminal peptide.our data show that the ubiquitin core and the ubiquitin
C terminus alone bind USP2 very weakly with affinities
at best in the high micromolar range, while full-length
ubiquitin inhibits USP2 with a Ki of 2.8 mM.
Discussion
USP2 is one of 54 human members of the family of ubiq-
uitin-specific proteases (USPs). USPs belong to the clan
CA of papain-like proteases (http://merops.sanger.ac.
uk/), which are characterized by catalytic residues in
the order Cys, His, Asp/Asn in sequence, with the active
site cysteine located at the beginning of a central a helix.
Despite large sequence and structural divergence
among the different representatives of this clan, the res-
idues of the catalytic triad superimpose well (Johnston
et al., 1997; Hu et al., 2002). Therefore, it has been sug-
gested that members of clan CA share the catalytic
mechanism with the active site cysteine and histidine
residues forming a thiolate-imidazolium ion pair (Storer
and Menard, 1994). Mutagenesis studies on USP7 (Hu
et al., 2002) corroborate the importance of these resi-
dues for the catalytic activity of USPs. Yet, USPs differ
fundamentally from other papain-like proteases as
they require ubiquitin to reach full catalytic activity.
While USP5 cleaves ubiquitin-derivatized substrates at
rates close to diffusion control, short peptidic sub-
strates containing the C-terminal residues of ubiquitin
are turned over at significantly lower rates (Stein et al.,
1995). In addition, ubiquitin binds to and inhibits USP5.
The structures of USP7 in the absence and presence
of ubiquitin-aldehyde gave a first structural explanation
for the high substrate selectivity of USPs (Hu et al.,
2002). Only when ubiquitin is bound does the enzyme
adopt a catalytic-competent conformation. In the ab-
sence of ubiquitin, active-site residues and residues de-
lineating the substrate binding sites are misaligned. Yet,
as the structural rearrangements are restricted to the
vicinity of the active site, where the C-terminal residues
Figure 4. USP2 Inhibition by Full-Length Ubiquitin and the C-Termi-
nally Truncated Mutants, Ubiquitin 1-74 and 1-73
Residual enzymatic activity was determined at 22C with ubiquitin-
AMC as substrate. The relative activity (vi/vo) is plotted against the
inhibitor concentration. From these data, the corresponding Kis
were deduced as described in the Experimental Procedures section.
The assay was performed in triplicate; the figure shows one repre-
sentative set of measurements.
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mimicking the ubiquitin C terminus are poor USP
substrates.
In line with the data published for USP5 (Stein et al.,
1995), we show that USP2 turns over ubiquitin-AMC
with a high catalytic efficiency (kcat/KM of 2.5 3 10
5
M21s21), while it is unable to cleave peptidic AMC sub-
strates consisting of five or nine amino acids from the
ubiquitin C terminus. At first sight, these results suggest
that the core of ubiquitin and not its C terminus are re-
quired for the binding to USP2. Consequently, the
main contribution for the binding affinity results from in-
teractions between the ubiquitin core (residues 1–71)
and the USP2 fingers and palm domains. To test this hy-
pothesis, several C-terminal-truncated ubiquitin mu-
tants were analyzed in USP2 inhibition assays. While
ubiquitin inhibits USP2 with a Ki of 2.8 mM, mutants lack-
ing residues Arg74-Gly75-Gly76 or Leu73-Arg74-Gly75-
Gly76 affect the proteolytic activity of USP2 only mar-
ginally even at the highest inhibitor concentration. In
summary, the interactions between the ubiquitin core
and the fingers/palm as well as the one between the
ubiquitin C terminus and the active site cleft are very
weak, and both interactions are required simultaneously
for ubiquitin binding. The weak affinities of the C-termi-
nal ubiquitin peptides together with the methods avail-
able in the kinetic analysis do not allow the determina-
tion of the exact Ki values for the inhibition of USP2.
Therefore, it remains unknown whether the binding to
the two low-affinity sites is cooperative or purely addi-
tive. Yet, cooperative binding seems likely: based on
the analogy to USP7, we assume that prior to ligand
binding, the active site of USP2 is in a catalytically in-
competent conformation. In this conformation, the two
active-site residues cysteine and histidine are too far
apart to form a catalytic diad, and the substrate binding
site at the catalytic center is absent. When ubiquitin
binds to USP2, its core is recognized by the cupped
hand. This interaction aligns the ubiquitin C terminus
into the right orientation and register, so that it can
bind to the active site cleft and induce the active confor-
mation of the enzyme. Isolated C-terminal fragments
cannot be prealigned. Therefore they bind with very
low affinity and are unable to induce an active conforma-
tion. For the design of low molecular weight active-site-
directed inhibitors of USP2, these findings suggest that,
in order to gain potency, the ligand has to bind in such an
induced-fit binding mode. This might only be achievable
if the inhibitor spans both interaction sites.
Interestingly, a ubiquitin mutant lacking Gly75-Gly76
is a slightly more potent USP2 inhibitor than full-length
ubiquitin (Ki of 1.0 mM versus 2.8 mM). This suggests
that the two C-terminal ubiquitin residues make no
significant net contribution to the USP2/ubiquitin
interaction. This is surprising, as, in the USP2/ubiquitin
complex structure, the Gly75-Gly76 dipeptide binds
into a narrow channel formed by the highly conserved
residue Gln293 and is engaged in five potential H bond
interactions. A possible explanation is the charge-
charge repulsion between the negatively charged
Gly76 carboxylate and the Cys223 Sg, which we assume
to be negatively charged based on the analogy to papain
(see above). This repulsion leads to the observed re-
orientation of Cys223 and the destabilization of theprotease/ligand complex. By contrast, in a putative
USP2/ubiquitin 1–74 complex, the distance between
the two negative charges is increased by at least 7 A˚.
At this distance, the repulsion between the ubiquitin C
terminus and the USP2 active-site cysteine is reduced.
The interaction is strengthened, and the loss of the five
potential H bonds more than compensated.
Based on the USP7 (Hu et al., 2002) and USP14 (Hu
et al., 2005) structures, it has been predicted that the
overall fold is conserved among USPs. Despite signifi-
cant variations between different USP sequences,
several elements required for ubiquitin recognition are
allegedly shared by functional USPs. Most of these
elements are found in USP2 as well. Yet, besides con-
servation of key residues at the tip of the fingers, resi-
dues forming the binding site for the ubiquitin core are
diverse in the USP family, namely between USP2 and
USP7 (Figure 1). Still, USP2 and USP7 bind ubiquitin in
the same way. In the absence of sequence conservation,
the interactions between ubiquitin and the USP are con-
served by a layer of water molecules. Eleven of these
water molecules are found at identical positions in the
USP2 and USP7 complexes (Figure 2F). They are placed
along strands s1, s2, and s3, regions of diverse se-
quence, and mediate H bond interactions between ubiq-
uitin and main-chain atoms of USP2. The conservation
of specific USP/ubiquitin interactions in the absence of
sequence conservation is illustrated by the interactions
with ubiquitin Lys6 carbonyl oxygen. In the USP2/ubiq-
uitin complex, Nz of Lys407 occupies the same position
as a solvent molecule in the USP7/ubiquitin-aldehyde
complex.
The principles of protein-protein interactions and the
role of water molecules in molecular recognition have
been studied by various groups (Janin, 1997; Jones
and Thornton, 1996; Larsen et al., 1998). ‘‘Wet’’ pro-
tein-protein interfaces where a large fraction of inter-
actions are water mediated are not uncommon but are
less abundant then complexes where the contact inter-
face is largely dehydrated (Janin, 1997). For example,
water-mediated interactions have been reported for
the L-arabinose binding protein (Quiocho et al., 1989), the
barnase-barstar complex (Buckle et al., 1994), and the
Streptomyces griseus protease B-ovomucid complex
(Huang et al., 1995). The contribution of water-mediated
interactions to the binding affinity is difficult to assess
both experimentally and theoretically (Rodier et al.,
2005). In general, hydrophobic interactions are tighter
than polar interactions (Tsai et al., 1997), while water-
mediated and direct polar interactions are believed to
be of similar strength (Rodier et al., 2005). The USP2-
ubiquitin interface in the area of the ubiquitin core
(1–71) appears to be less hydrophobic than protease-in-
hibitor interfaces in general. This is no surprise, as ubiq-
uitin has to dissociate from USP2 once it is cleaved off
its target protein and should not act as a tight inhibitor.
In the USP-ubiquitin complexes, the solvent molecules
fill parts of the cavity formed at the protein-protein inter-
face and act as a coating that prevents the two mole-
cules from interacting directly. They provide specific,
conserved interaction sites. We hypothesize that this
mode of substrate recognition is common to all USPs
and that mediating water molecules will also be found
in other USP/ubiquitin complexes.
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USP2 and UCH-L3 Preparation
The boundaries of the catalytic domain of human USP2 have been
defined by aligning different USP2 isoforms and orthologs. The cat-
alytic core, Asn259 to Met605, was amplified by PCR from a cDNA
encoding for full-length human USP2 (UniProt ID O75604) with the
sense 50-CTGAATTCGGATCCGCCGCCATGGCACATATGAATTC
TAAGAGTGCCCAG-30 and the antisense primer 50-GACTCGAGT
TACTATGCGGCCGCCATTCGGGAGGGCGGGCTG-30 into a modi-
fied pET24a vector (Novagen) in frame with the C-terminal His tag
by using the restriction enzymes NdeI/NotI.
E. coli strain Rosetta (DE3)pLysS harboring the human USP2 ex-
pression plasmid was cultivated at 37C in LB medium (30 mg/ml
kanamycin, 34 mg/ml chloramphenicol) and induced at an OD600 of
0.5–0.8 with 0.5 mM IPTG. After 2–5 hr of induction, the cells were
harvested by centrifugation and frozen at220C. Cells from a 4 liter
E. coli cell culture were resuspended in 200–300 ml buffer A (10 mM
Tris/HCl [pH 8.0], 100 mM NaCl), supplemented with 10 mM PMSF
(Sigma), 10 mM benzamidine (Sigma), 2 mM TCEP (Sigma), 1 mM
MgCl2, 10 mg/ml DNase I (Roche), and 100 mg/ml lysozyme (Sigma),
and ruptured by sonification. After centrifugation, the supernatant
was loaded on a Chelating Sepharose Fast Flow (Amersham)
column, which had been charged with 200 mM nickel sulfate. The
column was washed with buffer A supplemented with 15 mM imid-
azole. USP2 was eluted in one step with buffer A supplemented
with 250 mM imidazole.
In a second purification step, the sample was applied to a size ex-
clusion chromatography column (Superdex 75, HiLoad 26/60, Amer-
sham) equilibrated with 45 mM potassium phosphate (pH 6.0),
300 mM NaCl. Fractions containing USP2 were diluted 1:3 in water
and concentrated in an Amicon ultracentrifugation device (10 kDa
cutoff) to concentrations ranging from 10 to 50 mg/ml. The concen-
trated protein was flash frozen as 20–50 ml aliquots in liquid nitrogen
and stored at 280C. The overall yield was up to 50 mg protein per
one liter expression culture.
Human UCH-L3 was amplified from a cDNA library with the
sense 50-CTACTAGTGGCCATATGGAATCCATGGAGGGTCAACGC
TGGCTG-30 and the antisense primer 50-CTCGAGCTCGAGCTATGC
TGCAGAAAGAGCAAT-30 and cloned into pET28a (Novagen) by
using the restriction enzymes NcoI/XhoI. The encoded protein is
full-length UCH-L3 without N- or C-terminal tags and was purified
as described (Larsen et al., 1996). In the final purification step,
UCH-L3 was eluted from the size-exclusion chromatography
column (Superdex 75, HiLoad 26/60, Amersham) in 30 mM Tris
(pH 8.0), 300 mM NaCl and treated as described for USP2. The over-
all yield was typically 40 mg pure protein per one liter expression
culture.
Ubiquitin Preparation
Ubiquitin was amplified from a cDNA containing human ubiquitin
precursor ubiquitin B (UBB) with the sense 50-AAAAAAACATATGCA
GATCTTCGTGAAGACCCTG-30 and the antisense 50-TTTGGATCCT
CAGCCACCCCTCAGGCGCAGGACC-30 and cloned into pET24a
vector (Novagen) by using the restriction enzymes NdeI/BamHI.
The plasmid encodes for mature human ubiquitin 1–76, K48R with-
out any N- or C-terminal tags, hereon referred to as ‘‘ubiquitin.’’
Three C-terminal truncated ubiquitin mutants were generated with
the antisense primers 50-TTTGGATCCTCACCTCAGGCGCAGGAC
CAGGTGC-30, 50-TTTGGATCCTCACAGGCGCAGGACCAGGTGCA
GGG-30, and 50-TTTGGATCCTCAGCGCAGGACCAGGTGCAGGG
TCG-30. These plasmids encode for ubiquitin 1–74, lacking residues
Gly75 and Gly76, ubiquitin 1–73, lacking residues Arg74, Gly75, and
Gly76, and ubiquitin 1–72, lacking residues Leu73 to Gly76.
Ubiquitin, ubiquitin 1–74, ubiquitin 1–73, and ubiquitin 1–72 were
expressed and purified as described (Rajesh et al., 1999). The last
purification step was a size-exclusion chromatography (Superdex
75, HiLoad 26/60, Amersham) in 50 mM Tris (pH 8), 50 mM NaCl.
Ubiquitin-containing fractions were concentrated in Amicon ultra-
centrifugation devices (5 kDa cutoff), flash frozen in 50 ml aliquots,
and stored at 280C.
Prior to biophysical characterization of these proteins, the sample
buffers were changed from 50 mM Tris (pH 8), 50 mM NaCl to
50 mM Tris-D11 (fully deuterated, Cambridge Isotope Laboratories)(pH 7.5), 100 mM NaCl in D2O with desalting spin columns (Pierce).
The samples were first analyzed by one-dimensional 1H-NMR
spectroscopy (DRX600, Bruker) and subsequently by differential
scanning calorimetry (VP Capillary-DSC, MicroCal). Commercially
available ubiquitin (Sigma U6253), which is purified from bovine thy-
mus, was used as a reference. Please note that bovine ubiquitin is
identical to heterologously expressed human ubiquitin 1–76, with
the exception of the K48R mutation.
Kinetic Methods
Kinetic analysis was performed at 22C by using an Ultra microtiter
plate reader (TECAN) with a 360 nm/465 nm filter pair. In a typical ex-
periment, 10 ml assay buffer was transferred to a 384-well plate (Clin-
iplate black, Labsystems) and mixed with 10 ml of enzyme and 10 ml
of substrate solution. The final buffer was 50 mM Tris/HCl (pH 7.5),
1 mM EDTA, 5 mM DTE, 100 mM NaCl, 0.1% (w/v) CHAPS. The
enzyme concentration was determined from its absorbance at
280 nm. Previous titration experiments with ubiquitin-aldehyde
(Boston Biochem) have shown that our enzyme preparations were
>95% active. Data analysis was done with Origin 6.1 (Microcal).
Kinetic parameters were determined for the fluorogenic sub-
strates ubiquitin-AMC (ubiquitin C-terminally derivatized with fluo-
rogenic 7-amido-4-methylcoumarin, Boston Biochem), RLRGG-
AMC, and HLVLRLRGG-AMC (both Biosyntan). Initial velocities in
triplicates were plotted versus substrate concentration ranging
from 0 to 20 mM, and KM and vmax were calculated in a nonlinear re-
gression fit with the Michaelis-Menten equation v = (vmax3 [S])/([S] +
KM). The kcat was obtained from the equation kcat = vmax/[Eo], where
[Eo] is the total enzyme concentration. In these assays, the final
enzyme concentration was 3 pM for UCH-L3 and 1.5 nM for USP2.
For determination of the inhibition constants Ki, UCH-L3 (1 pM
enzyme) or USP2 (0.5 nM enzyme) were incubated with varying con-
centrations (0–100 mM) of inhibitor (ubiquitin, ubiquitin truncation
mutants, and C-terminal peptide Ac-HLVLRLRGG-OH) in the assay
buffer for 60 min at 22C. Residual enzymatic activity was deter-
mined by measuring the rate of hydrolysis ubiquitin-AMC by USP2
(5 mM substrate) and UCH-L3 (0.5 mM substrate) in triplicate. The ap-
parent inhibition constant for each enzyme-inhibitor pair was deter-
mined from the uninhibited rate (vo) and inhibited rates (vi) by plot-
ting vi/vo versus the inhibitor concentration. In such a plot, the
slope equals 1/Ki(apparent). For competitive inhibition, the inhibition
constant is defined as Ki = Ki (apparent)/(1 + [S]/KM), where [S] is the
concentration of ubiquitin-AMC. Please note that the competitive
mechanism of inhibition has not been shown experimentally. In
a competitive mechanism, inhibitor and substrate compete for the
same binding site, which is most likely the case as ubiquitin-AMC
and the inhibitor, ubiquitin and its deletion mutants, are almost
identical molecules.
Complex Formation, Crystallization, and Data Collection
The USP2/ubiquitin complex was formed by mixing 40 ml USP2
(11.8 mg/ml in 15 mM potassium phosphate [pH 6.0], 100 mM
NaCl, 25 mM DTT) and 20 ml ubiquitin (Sigma U6253, 10 mg/ml in
H2O demin) corresponding to a 1:2 molar ratio. Initial sparse matrix
screens were set up at 23C after incubation at 4C overnight. By
using an Oryx 6 crystallization robot (Douglas Instruments), 0.5 ml
premade solution (Index screen, Hampton Research) was added
to 0.5 ml of the protein complex in a modified microbatch format
(D’Arcy et al., 2003). Crystals grew within 24 hr in eight out of 96 con-
ditions. All these conditions contained polyethylene glycol or poly-
ethylene glycol monomethyl ether as the primary precipitating
agent. No crystals were obtained when identical crystallization trials
were set up with either free USP2 or free ubiquitin. Analysis of crys-
tals by SDS-PAGE showed the presence of both USP2 and ubiquitin
(data not shown).
A crystal cryo-mounted directly from the first initial screen
(200 mM MgCl2, 100 mM Bis-Tris [pH 6.5], 25% w/v PEG 3350) ini-
tially diffracted to only 4 A˚ on a Nonius FR591 rotating anode oper-
ated at 5 kW equipped with a MAR345 imaging plate detector. In an
attempt to improve the diffraction quality, we applied a simple, re-
cently published dehydration protocol (Abergel, 2004). The same
crystal was transferred to 10 ml of the crystallization solution supple-
mented with 30% glycerol as a cryoprotectant. During this process
the crystal cracked. A single piece was isolated, placed in 10 ml of the
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1301same solution, and dehydrated for 30 min at 23C. Then, the crystal
was mounted and flash frozen again. This procedure lead to a signif-
icant improvement of the diffraction quality (maximum resolution
2.5 A˚ on FR591 generator), and spots could be observed up to
1.65 A˚ on a FR-E SuperBright generator operated at 2 kW equipped
with a Saturn92 CCD detector (both Rigaku). Due to the small size of
the detector (92 mm 3 92 mm), its rectangular shape, and the low
crystal symmetry, the completeness of the high-resolution data
was acceptable only up to 1.85 A˚, despite collecting data in three
swipes at different 2t, k, and 4 angles. Data sets were integrated
and scaled with XDS (Kabsch, 1993) as part of the APRV package
(Kroemer et al., 2004). For data collection statistics see Table 3.
Structure Determination and Refinement
The structure was determined by molecular replacement with
Phaser (Storoni et al., 2004). Search models were taken from the
PDB (ubiquitin, 1OGW; USP7, 1NBF chain C residues 211 to 533
without the 494 to 512 loop). One ubiquitin molecule and one
USP7 catalytic domain could be placed in the asymmetric unit. To
avoid clashes, several surface loops had to be removed. At this
stage, the sequence of the model was changed to corresponding
USP2 residues only in areas where the sequence alignment between
USP2 and USP7 was unambiguous. Elsewhere, the sequence was
changed to alanines. Starting from this modified model, 336 of 435
(359 USP2 and 76 ubiquitin residues) residues could be traced auto-
matically in ARP/wARP (Perrakis et al., 1997), and an additional 53
residues could be placed manually with Main (Turk, 1992) for visual
inspection and CNX (Accelrys) for refinement. The resulting model
lacks 46 amino acids. For structure refinement statistics see Table
3. Figures were made in Pymol (DeLano Scientific, http://www.
pymol.org/).
Table 3. Crystallographic Data and Refinement Statistics
Data Set Statistics




Completeness (%) 95.5 (81.8)
Number of observations 116,236
Number of reflections 28,474
Crystal
Space group C2
a, b, c (A˚) 106.9, 45.5, 76.4
a, b, g () 90, 110, 90
Refinement Statistics
Resolution (A˚) 41.47–1.85 (1.97–1.85)
Number of reflections 28,473 (3923)
Completeness working + test set 95.5









Bond length rmsd (A˚) 0.016
Bond angles rmsd () 1.5
Ramachandron plot (core, allowed,
generous) (%)
93.4, 6.0, 0.6
The values in parentheses correspond to the highest resolution
shell.
a Rsym= SjI2 <I>j/SI, where I is the observed intensity, and <I> is the
average intensity from multiple observations of symmetry-related
reflections.
b Rcryst = Sj(Fo) 2 (Fc)j/S(Fo), where Fo and Fc are observed and cal-
culated structure factors, respectively. Rfree is the R factor calcu-
lated for a 5% subset of reflections selected at random.Supplemental Data
Supplemental Data include the description of an MAD experiment
that was used for the determination of the metal bound to the zinc
ribbon present in USP2 and are available online at http://www.
structure.org/cgi/content/full/14/8/1293/DC1/.
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